Understanding cost effectiveness in neurology
The USA spends more in healthcare per capita than any other country in the world, but ranks last among high-income industrialized nations in major markers of healthcare effectiveness such as life expectancy, maternal mortality, neonatal mortality, and infant mortality. Unlike other high-income indus...
Gespeichert in:
| Veröffentlicht in: | Journal of the neurological sciences 2023-12, Vol.455, p.122787-122787, Article 122787 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122787 |
|---|---|
| container_issue | |
| container_start_page | 122787 |
| container_title | Journal of the neurological sciences |
| container_volume | 455 |
| creator | Sánchez Fernández, Iván |
| description | The USA spends more in healthcare per capita than any other country in the world, but ranks last among high-income industrialized nations in major markers of healthcare effectiveness such as life expectancy, maternal mortality, neonatal mortality, and infant mortality. Unlike other high-income industrialized nations, the USA does not have a national agency that systematically evaluates the cost-effectiveness of health care interventions and negotiates their price accordingly. This manuscript aims to introduce the rationale, terminology, advantages, and limitations of cost-effectiveness analysis. Cost-effectiveness analysis compares health interventions and evaluates their incremental value and their incremental cost compared with already existing healthcare interventions. Cost-effectiveness analysis integrates the best available evidence with patients' preferences to inform clinical decision making. Patients with neurological conditions are facing increasing challenges to access healthcare and prescription drugs. Cost-effectiveness analysis may help improve access to the most effective healthcare interventions and prescription drugs while containing healthcare costs. |
| doi_str_mv | 10.1016/j.jns.2023.122787 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2891753690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2891753690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-34bd1764fcd9e5c65332b36c0eddd456bf85ebcdd1072f0370605609987481ba3</originalsourceid><addsrcrecordid>eNo90DtPwzAUBWALgWgp_AAWlJEl4dqOXyOqeEmVWKjEZiX2dZUodUqcIPHvadXCdJZzzvARckuhoEDlQ1u0MRUMGC8oY0qrMzKnWulcaM3PyRyAsVxQ-JyRq5RaAJBam0sy48ooU9JyTvJ19DiksYq-iZvM9WnMMAR0Y_ONEVPKmphFnIa-6zc_1-QiVF3Cm1MuyPr56WP5mq_eX96Wj6vccaBjzsvaUyXL4LxB4aTgnNVcOkDvfSlkHbTA2nlPQbEAXIEEIcEYrUpN64ovyP3xdzf0XxOm0W6b5LDrqoj9lCzThirBpYF9lR6rbuhTGjDY3dBsq-HHUrAHJdvavZI9KNmj0n5zd7qf6i36_8UfC_8FHm5jMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891753690</pqid></control><display><type>article</type><title>Understanding cost effectiveness in neurology</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sánchez Fernández, Iván</creator><creatorcontrib>Sánchez Fernández, Iván</creatorcontrib><description>The USA spends more in healthcare per capita than any other country in the world, but ranks last among high-income industrialized nations in major markers of healthcare effectiveness such as life expectancy, maternal mortality, neonatal mortality, and infant mortality. Unlike other high-income industrialized nations, the USA does not have a national agency that systematically evaluates the cost-effectiveness of health care interventions and negotiates their price accordingly. This manuscript aims to introduce the rationale, terminology, advantages, and limitations of cost-effectiveness analysis. Cost-effectiveness analysis compares health interventions and evaluates their incremental value and their incremental cost compared with already existing healthcare interventions. Cost-effectiveness analysis integrates the best available evidence with patients' preferences to inform clinical decision making. Patients with neurological conditions are facing increasing challenges to access healthcare and prescription drugs. Cost-effectiveness analysis may help improve access to the most effective healthcare interventions and prescription drugs while containing healthcare costs.</description><identifier>ISSN: 0022-510X</identifier><identifier>EISSN: 1878-5883</identifier><identifier>DOI: 10.1016/j.jns.2023.122787</identifier><identifier>PMID: 37979414</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Cost-Benefit Analysis ; Cost-Effectiveness Analysis ; Health Care Costs ; Humans ; Infant ; Infant, Newborn ; Neurology</subject><ispartof>Journal of the neurological sciences, 2023-12, Vol.455, p.122787-122787, Article 122787</ispartof><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c301t-34bd1764fcd9e5c65332b36c0eddd456bf85ebcdd1072f0370605609987481ba3</citedby><cites>FETCH-LOGICAL-c301t-34bd1764fcd9e5c65332b36c0eddd456bf85ebcdd1072f0370605609987481ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37979414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sánchez Fernández, Iván</creatorcontrib><title>Understanding cost effectiveness in neurology</title><title>Journal of the neurological sciences</title><addtitle>J Neurol Sci</addtitle><description>The USA spends more in healthcare per capita than any other country in the world, but ranks last among high-income industrialized nations in major markers of healthcare effectiveness such as life expectancy, maternal mortality, neonatal mortality, and infant mortality. Unlike other high-income industrialized nations, the USA does not have a national agency that systematically evaluates the cost-effectiveness of health care interventions and negotiates their price accordingly. This manuscript aims to introduce the rationale, terminology, advantages, and limitations of cost-effectiveness analysis. Cost-effectiveness analysis compares health interventions and evaluates their incremental value and their incremental cost compared with already existing healthcare interventions. Cost-effectiveness analysis integrates the best available evidence with patients' preferences to inform clinical decision making. Patients with neurological conditions are facing increasing challenges to access healthcare and prescription drugs. Cost-effectiveness analysis may help improve access to the most effective healthcare interventions and prescription drugs while containing healthcare costs.</description><subject>Cost-Benefit Analysis</subject><subject>Cost-Effectiveness Analysis</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Neurology</subject><issn>0022-510X</issn><issn>1878-5883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90DtPwzAUBWALgWgp_AAWlJEl4dqOXyOqeEmVWKjEZiX2dZUodUqcIPHvadXCdJZzzvARckuhoEDlQ1u0MRUMGC8oY0qrMzKnWulcaM3PyRyAsVxQ-JyRq5RaAJBam0sy48ooU9JyTvJ19DiksYq-iZvM9WnMMAR0Y_ONEVPKmphFnIa-6zc_1-QiVF3Cm1MuyPr56WP5mq_eX96Wj6vccaBjzsvaUyXL4LxB4aTgnNVcOkDvfSlkHbTA2nlPQbEAXIEEIcEYrUpN64ovyP3xdzf0XxOm0W6b5LDrqoj9lCzThirBpYF9lR6rbuhTGjDY3dBsq-HHUrAHJdvavZI9KNmj0n5zd7qf6i36_8UfC_8FHm5jMA</recordid><startdate>20231215</startdate><enddate>20231215</enddate><creator>Sánchez Fernández, Iván</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231215</creationdate><title>Understanding cost effectiveness in neurology</title><author>Sánchez Fernández, Iván</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-34bd1764fcd9e5c65332b36c0eddd456bf85ebcdd1072f0370605609987481ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cost-Benefit Analysis</topic><topic>Cost-Effectiveness Analysis</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Neurology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sánchez Fernández, Iván</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sánchez Fernández, Iván</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding cost effectiveness in neurology</atitle><jtitle>Journal of the neurological sciences</jtitle><addtitle>J Neurol Sci</addtitle><date>2023-12-15</date><risdate>2023</risdate><volume>455</volume><spage>122787</spage><epage>122787</epage><pages>122787-122787</pages><artnum>122787</artnum><issn>0022-510X</issn><eissn>1878-5883</eissn><abstract>The USA spends more in healthcare per capita than any other country in the world, but ranks last among high-income industrialized nations in major markers of healthcare effectiveness such as life expectancy, maternal mortality, neonatal mortality, and infant mortality. Unlike other high-income industrialized nations, the USA does not have a national agency that systematically evaluates the cost-effectiveness of health care interventions and negotiates their price accordingly. This manuscript aims to introduce the rationale, terminology, advantages, and limitations of cost-effectiveness analysis. Cost-effectiveness analysis compares health interventions and evaluates their incremental value and their incremental cost compared with already existing healthcare interventions. Cost-effectiveness analysis integrates the best available evidence with patients' preferences to inform clinical decision making. Patients with neurological conditions are facing increasing challenges to access healthcare and prescription drugs. Cost-effectiveness analysis may help improve access to the most effective healthcare interventions and prescription drugs while containing healthcare costs.</abstract><cop>Netherlands</cop><pmid>37979414</pmid><doi>10.1016/j.jns.2023.122787</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-510X |
| ispartof | Journal of the neurological sciences, 2023-12, Vol.455, p.122787-122787, Article 122787 |
| issn | 0022-510X 1878-5883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2891753690 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Cost-Benefit Analysis Cost-Effectiveness Analysis Health Care Costs Humans Infant Infant, Newborn Neurology |
| title | Understanding cost effectiveness in neurology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T23%3A36%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20cost%20effectiveness%20in%20neurology&rft.jtitle=Journal%20of%20the%20neurological%20sciences&rft.au=S%C3%A1nchez%20Fern%C3%A1ndez,%20Iv%C3%A1n&rft.date=2023-12-15&rft.volume=455&rft.spage=122787&rft.epage=122787&rft.pages=122787-122787&rft.artnum=122787&rft.issn=0022-510X&rft.eissn=1878-5883&rft_id=info:doi/10.1016/j.jns.2023.122787&rft_dat=%3Cproquest_cross%3E2891753690%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2891753690&rft_id=info:pmid/37979414&rfr_iscdi=true |